MARKET

IBIO

IBIO

IBIO
AMEX

Real-time Quotes | Nasdaq Last Sale

1.170
+0.020
+1.74%
Pre Market: 1.170 0 0.00% 08:53 09/24 EDT
OPEN
1.140
PREV CLOSE
1.150
HIGH
1.170
LOW
1.140
VOLUME
21.91K
TURNOVER
--
52 WEEK HIGH
2.830
52 WEEK LOW
1.030
MARKET CAP
254.88M
P/E (TTM)
-7.3631
1D
5D
1M
3M
1Y
5Y
iBio to Participate in the Cantor 2021 Virtual Global Healthcare Conference
BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that the C...
GlobeNewswire · 3d ago
iBio to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update on Monday, September 27, 2021
BRYAN, Texas, Sept. 20, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, announced today that it wi...
GlobeNewswire · 4d ago
iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference
BRYAN, Texas, Sept. 07, 2021 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming Manufacturing System®, today announced that it wi...
GlobeNewswire · 09/07 20:30
iBio Inc. stock underperforms Friday when compared to competitors
marketwatch.com · 09/03 20:59
iBio Inc. stock rises Wednesday, outperforms market
marketwatch.com · 09/01 20:59
iBio Inc. stock remains steady Tuesday, still outperforms market
marketwatch.com · 08/31 20:59
iBio Inc. stock falls Thursday, underperforms market
marketwatch.com · 08/26 20:59
iBio Expands Immuno-Oncology Pipeline With RubrYc Deal
Benzinga · 08/25 15:16
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IBIO. Analyze the recent business situations of IBIO through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IBIO stock price target is 2.500 with a high estimate of 3.000 and a low estimate of 2.000.
EPS
Institutional Holdings
Institutions: 16
Institutional Holdings: 332.24K
% Owned: 0.15%
Shares Outstanding: 217.85M
TypeInstitutionsShares
Increased
4
14.06K
New
2
19.83K
Decreased
3
6.98K
Sold Out
1
250
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.99%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Chairman/President/Chief Executive Officer/Director
Thomas Isett
Chief Financial Officer/Chief Accounting Officer
Robert Lutz
Chief Operating Officer
Randy Maddux
Chief Scientific Officer
Martin Brenner
Treasurer/Secretary/Director
Robert Kay
Director
William Clark
Director
Evert Schimmelpennink
Independent Director
Linda Armstrong
Independent Director
Glenn Chang
Independent Director
James Hill
Independent Director
Alexandra Kropotova
Independent Director
John McKey
Independent Director
Gary Sender
No Data
About IBIO
iBio, Inc. is a biotechnology company. The Company is focused on commercializing its technologies and product candidates and providing product development and manufacturing services to clients and collaborators. Its technologies include iBioLaunch technology and iBioModulator. The Company's technologies constitute a transformative platform for development and production of biologics in hydroponically grown green plants. The Company is focused on the commercialization of its plant-based protein expression technologies for vaccines and therapeutic proteins and on developing and commercializing select biopharmaceutical product candidates. The Company's technology is applicable in a range of product candidates, including products against fibrotic diseases, vaccines, enzyme replacements, monoclonal antibodies, and recombinant versions of marketed products that are derived from human blood plasma.

Webull offers kinds of Ibio Inc stock information, including AMEX:IBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBIO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IBIO stock methods without spending real money on the virtual paper trading platform.